Shares of Circio Holding ASA jumped 11.4% to NOK 14.70 on September 1 after the Oslo-listed biotech's first-half report unveiled dramatic improvements in its experimental gene-delivery platform and a financing package large enough to fund operations through 2030. Circio's Circular RNA Data Dazzle and a NOK 620 Million Cash Haul Ignite a Rally — But How Far Can Preclinical Promise Carry a Stock With Zero Revenue?
Shares of Oslo-listed Circio Holding surged 11.4% to NOK 14.70 on September 1, capping a 34.6% run in just five trading sessions, after the company's first-half report married blockbuster lab results with the kind of cash cushion most micro-cap biotechs can only dream about. The question now: does the science justify the sprint?
The Lab Numbers Keep Getting Bigger — And That's the Whole Investment Case. Circio reported up to 60-fold higher gene expression in brain (CNS) tissue across three separate targets , with a potential 200-fold-plus boost in heart expression compared with standard gene-therapy approaches. That matters because gene therapies often fail not because the science is wrong but because the dose needed is toxic. If Circio's circular RNA technology can produce the same therapeutic protein at a fraction of the dose, it may enable "substantial reductions in AAV dosing requirements, potentially improving patient safety." Notably, these figures have escalated quickly — just months ago, the company was reporting 40-fold gains in heart tissue and 50-fold in eye tissue . Rapid improvement is encouraging, but preclinical results in animals frequently don't translate to humans.
NOK 620 Million Buys Time, Not Revenue. The company secured approximately NOK 620 million (USD 65 million) in new capital, extending its cash runway to 2030 . For a pre-revenue firm that had only NOK 42 million in net cash as recently as March 31 , this is transformational — it removes near-term dilution fear and lets management run multi-year experiments. But investors should remember: this money funds research, not sales. There is no product on the market and none in human clinical trials yet.
Pharma Partners Are Circling, But No Licensing Deal Has Landed. The company has a fully funded big-pharma feasibility study in CNS , a new collaboration with Boston-based Full Circles Therapeutics on non-viral cell therapy , and a June partnership with China's GenAssist targeting muscle diseases . These validate the platform's appeal, yet none have produced licensing revenue. Disease-model efficacy data expected in the second half of 2026 represent the real value inflection points — if positive, they could trigger the kind of big-pharma licensing deal that would justify today's price.
The Bottom Line. The stock's five-day tear reflects genuine scientific momentum and financial security rare for a company this small. But every dollar of value here rests on animal data and future partnerships. Today's webcast could add fuel — or sober the room.